← Back to Screener
US Stock Screener
HomeScreensNewsWatchlist
...

OrthoPediatrics Corp. (KIDS) 10-Year Financial Performance & Capital Metrics

KIDS • • Industrial / General
HealthcareMedical DevicesOrthopedic & Musculoskeletal DevicesJoint Reconstruction & Orthopedic Implants
AboutOrthoPediatrics Corp., a medical device company, designs, develops, and markets anatomically appropriate implants and devices for the treatment of children with orthopedic conditions in the United States and internationally. The company offers trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products. Its products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail, PediLoc tibia, anterior cruciate ligament reconstruction systems, locking cannulated blades, locking proximal femurs, Spica Tables, RESPONSE Spine systems, Bandloc, Pediguard, Pediatric Nailing Platform, Femur system, Orthex, QuickPack, and ApiFix Mid-C system. The company serves pediatric orthopedic market, as well as pediatric orthopedic surgeons and caregivers. OrthoPediatrics Corp. was founded in 2006 and is headquartered in Warsaw, Indiana.Show more
  • Revenue $205M +37.6%
  • EBITDA -$10M -11.5%
  • Net Income -$38M -80.3%
  • EPS (Diluted) -1.64 -78.3%
  • Gross Margin 72.58% -3.0%
  • EBITDA Margin -5.1% +19.0%
  • Operating Margin -14.42% +19.8%
  • Net Margin -18.47% -31.0%
  • ROE -10.34% -86.3%
  • ROIC -5.92% -7.2%
  • Debt/Equity 0.23 +755.1%
  • Interest Coverage -11.26
Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

  • ✓Strong 5Y sales CAGR of 23.1%
  • ✓Trading at only 1.2x book value

✗Weaknesses

  • ✗Weak Piotroski F-Score: 3/9
  • ✗Negative free cash flow
  • ✗Trading more than 30% below 52-week high

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y24.07%
5Y23.06%
3Y27.81%
TTM19.9%

Profit (Net Income) CAGR

10Y-
5Y-
3Y-
TTM-60.36%

EPS CAGR

10Y-
5Y-
3Y-
TTM-58.54%

ROCE

10Y Avg-11.85%
5Y Avg-7.81%
3Y Avg-7.11%
Latest-7.06%

Peer Comparison

Joint Reconstruction & Orthopedic Implants
Select Columns
Size & Scale
Valuation
Per Share
Growth
Profitability
Quality & Returns
Safety & Leverage
TTM Growth
Famous Investor Metrics
Dividends
Latest Quarter
Momentum & Returns
Total Return (DRIP)
Technical
Volume & Trading
Shares & Dilution
Sector-Specific
NameMarket CapCurrent PriceP/E RatioRevenue Growth 1YNet MarginROEFCF YieldDebt/Equity
SYKStryker Corporation138.62B362.4946.7110.23%12.07%13.51%2.52%0.68
SNNSmith & Nephew plc13.96B32.8934.994.7%6.88%14.44%4.34%0.63
ZBHZimmer Biomet Holdings, Inc.17.59B88.7520.033.85%10.05%6.31%6.5%0.50
CNMDCONMED Corporation1.32B42.559.995%4.75%6.35%11.68%0.94
DHAIDIH Holding US, Inc.6.7K0.00-0.00-2.5%-13.8%
LFWDLifeward Ltd.13.23M0.72-0.2285.24%-121.82%-233.98%0.05
ANIKAnika Therapeutics, Inc.137.43M9.53-2.49-0.73%-40.83%-22.5%0.17
SNWVSANUWAVE Health, Inc.237.99M27.75-3.9559.99%-17.06%0.83%

Profit & Loss

Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Sales/Revenue+31M37.3M45.62M57.56M72.55M71.08M98.05M122.29M148.73M204.73M
Revenue Growth %0.31%0.2%0.22%0.26%0.26%-0.02%0.38%0.25%0.22%0.38%
Cost of Goods Sold+9.37M10.93M11.17M14.88M17.93M16.05M24.65M31.63M37.48M56.13M
COGS % of Revenue0.3%0.29%0.24%0.26%0.25%0.23%0.25%0.26%0.25%0.27%
Gross Profit+21.64M26.37M34.45M42.68M54.62M55.03M73.4M90.66M111.25M148.6M
Gross Margin %0.7%0.71%0.76%0.74%0.75%0.77%0.75%0.74%0.75%0.73%
Gross Profit Growth %0.3%0.22%0.31%0.24%0.28%0.01%0.33%0.24%0.23%0.34%
Operating Expenses+28.23M32.49M40.92M52.23M63.7M81.79M91.43M116.06M138M178.12M
OpEx % of Revenue0.91%0.87%0.9%0.91%0.88%1.15%0.93%0.95%0.93%0.87%
Selling, General & Admin26.44M30.27M37.5M47.5M57.95M70.17M85.73M104M126.12M167.09M
SG&A % of Revenue0.85%0.81%0.82%0.83%0.8%0.99%0.87%0.85%0.85%0.82%
Research & Development1.79M2.22M3.42M4.73M5.75M5.27M5.54M8.45M10.89M11.03M
R&D % of Revenue0.06%0.06%0.08%0.08%0.08%0.07%0.06%0.07%0.07%0.05%
Other Operating Expenses-31K030K-217K06.34M150K3.61M985K0
Operating Income+-6.59M-6.13M-6.47M-9.55M-9.08M-26.75M-18.02M-25.4M-26.75M-29.52M
Operating Margin %-0.21%-0.16%-0.14%-0.17%-0.13%-0.38%-0.18%-0.21%-0.18%-0.14%
Operating Income Growth %0.08%0.07%-0.06%-0.48%0.05%-1.95%0.33%-0.41%-0.05%-0.1%
EBITDA+-4.74M-4.22M-4.07M-6.66M-4.44M-18.75M-7.34M-12.3M-9.37M-10.44M
EBITDA Margin %-0.15%-0.11%-0.09%-0.12%-0.06%-0.26%-0.07%-0.1%-0.06%-0.05%
EBITDA Growth %0.15%0.11%0.04%-0.64%0.33%-3.22%0.61%-0.67%0.24%-0.11%
D&A (Non-Cash Add-back)1.85M1.9M2.4M2.89M4.64M8.01M10.68M13.1M17.39M19.08M
EBIT-6.62M-5.1M-6.44M-9.77M-9.15M-30.25M-17.87M-21.79M-25.77M-29.52M
Net Interest Income+-1.23M-1.48M-2.49M-2.25M-3.54M-3.41M-2.25M-2.42M198K-2.62M
Interest Income00000000198K0
Interest Expense1.23M1.48M2.49M2.25M3.54M3.41M2.25M2.42M02.62M
Other Income/Expense-1.26M-445K-2.46M-2.47M-3.61M-6.91M636K21.71M5.44M-12.41M
Pretax Income+-7.85M-6.57M-8.93M-12.03M-12.69M-33.67M-17.39M-3.69M-21.31M-41.93M
Pretax Margin %-0.25%-0.18%-0.2%-0.21%-0.17%-0.47%-0.18%-0.03%-0.14%-0.2%
Income Tax+00000-723K-1.13M-4.95M-338K-4.11M
Effective Tax Rate %1%1%1%1%1.08%0.98%0.94%-0.34%0.98%0.9%
Net Income+-7.89M-6.57M-8.93M-12.03M-13.73M-32.94M-16.26M1.26M-20.97M-37.82M
Net Margin %-0.25%-0.18%-0.2%-0.21%-0.19%-0.46%-0.17%0.01%-0.14%-0.18%
Net Income Growth %0.17%0.17%-0.36%-0.35%-0.14%-1.4%0.51%1.08%-17.67%-0.8%
Net Income (Continuing)-7.85M-6.57M-8.93M-12.03M-12.69M-32.94M-16.26M1.26M-20.97M-37.82M
Discontinued Operations0000000000
Minority Interest0000000000
EPS (Diluted)+-1.05-0.87-1.85-0.96-1.18-1.82-0.840.06-0.92-1.64
EPS Growth %0.18%0.17%-1.13%0.48%-0.23%-0.54%0.54%1.07%-16.59%-0.78%
EPS (Basic)-1.05-0.87-1.85-0.96-1.18-1.82-0.840.06-0.92-1.64
Diluted Shares Outstanding7.51M7.51M4.82M12.57M14.62M18.06M19.27M20.95M22.68M23.08M
Basic Shares Outstanding7.51M7.51M4.82M12.57M14.62M18.06M19.27M20.7M22.68M23.08M
Dividend Payout Ratio----------

Balance Sheet

Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Total Current Assets+22.47M20.83M69.56M97.16M128.06M158.43M133.65M226.72M226.5M237.17M
Cash & Short-Term Investments3.88M1.61M42.58M60.69M70.78M85.27M54.91M118.29M80.31M68.83M
Cash Only3.88M1.61M42.58M60.69M70.78M30.13M9.01M8.99M31.05M43.82M
Short-Term Investments0000055.14M45.9M109.3M49.25M25.01M
Accounts Receivable3.82M4.1M5.6M9.5M16.57M17.55M17.94M24.8M34.62M42.36M
Days Sales Outstanding44.9540.144.8360.2583.3590.1266.7974.0284.9575.52
Inventory14.55M14.89M20.55M25.71M38M52.99M57.57M78.19M105.85M117M
Days Inventory Outstanding566.96497.06671.35630.65773.431.21K852.58902.341.03K760.87
Other Current Assets0233K831K01.25M2.62M3.23M1.47M5.72M1.96M
Total Non-Current Assets+8.22M9.85M12.74M14.95M66.51M166.4M174.75M201.01M212.25M236.04M
Property, Plant & Equipment7.34M8.59M10.39M12.77M21.35M27.23M28.52M34.29M41.05M58.83M
Fixed Asset Turnover4.23x4.34x4.39x4.51x3.40x2.61x3.44x3.57x3.62x3.48x
Goodwill000026.18M70.51M72.35M86.82M83.7M93.84M
Intangible Assets887K1.26M2.35M2.18M18.97M64.25M69.76M79.9M84.56M81.18M
Long-Term Investments000053.26M00189.52M1.85M2.18M
Other Non-Current Assets0000-54.1M00-195.48M1.08M0
Total Assets+30.69M30.68M82.3M112.11M194.56M324.83M308.4M427.73M438.75M473.21M
Asset Turnover1.01x1.22x0.55x0.51x0.37x0.22x0.32x0.29x0.34x0.43x
Asset Growth %-0.14%-0%1.68%0.36%0.74%0.67%-0.05%0.39%0.03%0.08%
Total Current Liabilities+6.34M7.25M9.47M9.22M13.66M35.03M29.71M30.87M41.67M33.96M
Accounts Payable2M3.54M5.5M3.97M6.47M10.04M9.32M11.15M12.65M8.91M
Days Payables Outstanding77.89118.31179.5697.41131.63228.32138.1128.67123.1957.93
Short-Term Debt101K107K113K118K124K12.36M13M144K152K160K
Deferred Revenue (Current)1000K1000K1000K1000K1000K001000K00
Other Current Liabilities1.98M1.38M954K1.58M-1.63M8.09M2.04M6.88M7.39M8.89M
Current Ratio3.55x2.87x7.35x10.54x9.37x4.52x4.50x7.34x5.44x6.98x
Quick Ratio1.25x0.82x5.18x7.75x6.59x3.01x2.56x4.81x2.90x3.54x
Cash Conversion Cycle534.02418.86536.61593.48725.151.07K781.27847.69992.63778.46
Total Non-Current Liabilities+13.04M17.43M25.34M21.16M38.54M55.03M53.32M18.21M20.05M84.68M
Long-Term Debt13.04M17.43M25.34M21.16M26.07M13.83M15.22M763K9.91M72.96M
Capital Lease Obligations000063K323K293K005.66M
Deferred Tax Liabilities0000-63K10.17M8.9M5.95M5.48M0
Other Non-Current Liabilities0000030.71M28.91M11.49M4.66M6.06M
Total Liabilities19.38M24.68M34.81M30.37M52.2M90.06M83.03M49.08M61.72M118.64M
Total Debt+13.14M17.54M25.45M21.27M26.25M26.52M28.51M907K10.06M80.9M
Net Debt9.26M15.93M-17.13M-39.42M-44.52M-3.62M19.5M-8.08M-21M37.08M
Debt / Equity1.16x2.93x0.54x0.26x0.18x0.11x0.13x0.00x0.03x0.23x
Debt / EBITDA----------
Net Debt / EBITDA----------
Interest Coverage-5.36x-4.15x-2.60x-4.24x-2.57x-7.84x-8.02x-10.48x--11.26x
Total Equity+11.31M5.99M47.49M81.73M142.36M234.77M225.37M378.65M377.02M354.57M
Equity Growth %-0.37%-0.47%6.92%0.72%0.74%0.65%-0.04%0.68%-0%-0.06%
Book Value per Share1.510.809.866.509.7313.0011.7018.0816.6315.36
Total Shareholders' Equity11.31M5.99M47.49M81.73M142.36M234.77M225.37M378.65M377.02M354.57M
Common Stock1K1K2K4K4K5K5K6K6K6K
Retained Earnings-71.56M-78.13M-103.07M-115.09M-128.82M-161.77M-178.03M-176.77M-197.74M-235.56M
Treasury Stock0000000000
Accumulated OCI-6.24M0135K-623K-3K7.91M8.49M-5.4M-5.53M-10.77M
Minority Interest0000000000

Cash Flow

Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Cash from Operations+-892K-1.12M-7.22M-15.58M-17.77M-18.53M-13.06M-21.77M-27.05M-27.05M
Operating CF Margin %-0.03%-0.03%-0.16%-0.27%-0.24%-0.26%-0.13%-0.18%-0.18%-0.13%
Operating CF Growth %0.91%-0.25%-5.45%-1.16%-0.14%-0.04%0.3%-0.67%-0.24%-0%
Net Income-7.89M-6.57M-8.93M-12.03M-13.73M-32.94M-16.26M1.26M-20.97M-37.82M
Depreciation & Amortization1.85M1.9M2.4M2.89M4.67M8.01M10.68M13.1M17.39M19.08M
Stock-Based Compensation1.23M1.25M3.48M3.19M2.6M6.2M5.84M6.68M10.53M13.55M
Deferred Taxes-1.19M000-144K-723K-1.13M-5.03M-1.16M-4.74M
Other Non-Cash Items1.23M-889K12.25M19.09M210K5.92M354K-20.01M-623K5.82M
Working Capital Changes3.88M3.19M-4.17M-9.63M-11.38M-4.99M-12.55M-17.76M-32.2M-22.93M
Change in Receivables-1.05M-280K-1.5M-3.8M-5.82M-451K-466K-3.98M-9.72M-4.75M
Change in Inventory3.27M889K-4.41M-4.8M-9.77M-12.07M-5.05M-16.94M-26.28M-13.2M
Change in Payables1.35M1.54M1.95M-1.52M2.4M3.07M-567K-209K1.49M-4.28M
Cash from Investing+-1.71M-4.75M-6.54M-5.96M-61.92M-69.69M-7.41M-113.37M41.68M-13.16M
Capital Expenditures-2.25M-4.75M-6.54M-5.46M-12.09M-11.3M-16.01M-10.03M-16.88M-14.26M
CapEx % of Revenue0.07%0.13%0.14%0.09%0.17%0.16%0.16%0.08%0.11%0.07%
Acquisitions----------
Investments----------
Other Investing539K-406K-1.34M-502K0-796K-650K0-2.11M-2.88M
Cash from Financing+-98K3.6M54.73M39.66M91.02M46.73M6K135.97M7.3M53.13M
Debt Issued (Net)----------
Equity Issued (Net)----------
Dividends Paid00-5.96M0000000
Share Repurchases----------
Other Financing0-794K0410K1.14M1.65M0-3.17M-2M-3.41M
Net Change in Cash----------
Free Cash Flow+-3.14M-5.87M-13.76M-21.05M-29.86M-29.83M-29.07M-31.8M-46.03M-41.31M
FCF Margin %-0.1%-0.16%-0.3%-0.37%-0.41%-0.42%-0.3%-0.26%-0.31%-0.2%
FCF Growth %0.76%-0.87%-1.34%-0.53%-0.42%0%0.03%-0.09%-0.45%0.1%
FCF per Share-0.42-0.78-2.86-1.67-2.04-1.65-1.51-1.52-2.03-1.79
FCF Conversion (FCF/Net Income)0.11x0.17x0.81x1.30x1.29x0.56x0.80x-17.30x1.29x0.72x
Interest Paid0000000000
Taxes Paid0000000000

Key Ratios

Metric2015201620172018201920202021202220232024
Return on Equity (ROE)-53.88%-75.94%-33.4%-18.61%-12.25%-17.47%-7.07%0.42%-5.55%-10.34%
Return on Invested Capital (ROIC)-21.87%-21.62%-18.57%-19.72%-9.71%-12.2%-5.68%-6.19%-5.52%-5.92%
Gross Margin69.79%70.69%75.52%74.15%75.28%77.42%74.86%74.14%74.8%72.58%
Net Margin-25.45%-17.62%-19.58%-20.89%-18.93%-46.35%-16.58%1.03%-14.1%-18.47%
Debt / Equity1.16x2.93x0.54x0.26x0.18x0.11x0.13x0.00x0.03x0.23x
Interest Coverage-5.36x-4.15x-2.60x-4.24x-2.57x-7.84x-8.02x-10.48x--11.26x
FCF Conversion0.11x0.17x0.81x1.30x1.29x0.56x0.80x-17.30x1.29x0.72x
Revenue Growth30.91%20.3%22.31%26.17%26.05%-2.03%37.95%24.72%21.62%37.65%

Revenue by Segment

20172018201920202021202220232024
Trauma and Deformity32.8M39.7M49.37M47.68M65.83M85.06M106.78M145.13M
Trauma and Deformity Growth-21.02%24.38%-3.43%38.07%29.21%25.54%35.91%
Spine11.59M16.66M21.48M20.74M28.05M33.43M37.93M55.15M
Spine Growth-43.82%28.95%-3.48%35.24%19.19%13.48%45.40%
ACL Reconstruction and Other1.23M1.2M1.7M2.66M4.17M3.81M4.02M4.45M
ACL Reconstruction and Other Growth--2.59%41.10%57.02%56.74%-8.82%5.57%10.70%

Revenue by Geography

20172018201920202021202220232024
UNITED STATES34.91M43.46M55.05M62.97M77.78M92.42M111.01M161.16M
UNITED STATES Growth-24.50%26.68%14.37%23.53%18.82%20.12%45.18%
Non-US-14.1M17.5M8.11M20.27M29.87M37.72M43.56M
Non-US Growth--24.11%-53.64%149.85%47.38%26.29%15.49%

Frequently Asked Questions

Growth & Financials

OrthoPediatrics Corp. (KIDS) reported $227.4M in revenue for fiscal year 2024. This represents a 860% increase from $23.7M in 2014.

OrthoPediatrics Corp. (KIDS) grew revenue by 37.6% over the past year. This is strong growth.

OrthoPediatrics Corp. (KIDS) reported a net loss of $45.6M for fiscal year 2024.

Dividend & Returns

OrthoPediatrics Corp. (KIDS) has a return on equity (ROE) of -10.3%. Negative ROE indicates the company is unprofitable.

OrthoPediatrics Corp. (KIDS) had negative free cash flow of $29.4M in fiscal year 2024, likely due to heavy capital investments.

VCP Scanner

Find stocks. Verify deeply. Act with conviction.

Patterns find ideas. Fundamentals build conviction.

Data updated daily

Quick Links

  • Home
  • Screens
  • Valuation
  • Compare
  • Total Return
  • News
  • Insights
  • Methodology
  • How It Works
  • Profile

Popular Screens

  • VCP Hot
  • VCP Warm
  • Value Screens
  • Growth Screens
  • Momentum Screens
  • Technical Screens
  • Quality Screens

Community

  • Twitter
  • Get Early Access
© 2026 VCP Scanner. All rights reserved.
Made with ❤️ for investors
Not financial advice. Do your own research.